Answers are grounded in this paper and cite their sources.
Pyrazole derivatives represent an important class of heterocyclic compounds with diverse pharmacological applications, yet the electronic behavior and therapeutic potential of several derivatives remain insufficiently explored. This study aims to investigate the structural, spectroscopic, electronic, and pharmacological characteristics of 4-methyl-1-phenyl-3-pyrazolidone (4MP3P) as a potential AKT pathway inhibitor through combined experimental and computational approaches. Geometry optimization and quantum chemical calculations were performed using density functional theory at the B3LYP/6-311++G(d,p) level, followed by vibrational, UV-Vis, frontier orbital analyses. Drug-likeness and ADMET properties were predicted using in silico tools, while molecular docking and 100 ns molecular dynamics simulations evaluated interactions with the AKT protein (PDB ID: 8UW9). Antioxidant activity was experimentally assessed using a DPPH assay. The results demonstrated strong agreement between theoretical and experimental spectra and revealed a large HOMO-LUMO gap (5.177 eV), indicating molecular stability and moderate reactivity. Hyperconjugative interactions and charge transfer behavior supported electronic delocalization and molecular stability. Pharmacokinetic analysis indicated favorable oral absorption (83.17%) and a safe toxicity profile. Docking and simulation studies showed stable binding with AKT, with a binding affinity of −6.87 kcal/mol and consistent structural stability. The compound exhibited significant antioxidant activity with an IC50 of 44.1 mg/mL. The findings collectively indicate that 4MP3P is a structurally stable and pharmacologically viable compound exhibiting notable bioactivity and potential anticancer relevance, thereby justifying further experimental investigation.
No takes yet. Share an insight, caveat, or question.
Subha et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: